Search

Your search keyword '"Ursula La Rocca"' showing total 5 results
Start Over Author "Ursula La Rocca" Publication Year Range Last 3 years
5 results on '"Ursula La Rocca"'

1. Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS

Author

Chiara Masucci, Sara Pepe, Ursula La Rocca, Veronica Zullino, Maria Stefania De Propris, Walter Barberi, Anna Paola Iori, Sabina Martelli, Franco Ruberto, Maurizio Martelli, and Alice Di Rocco

Subjects
CAR T, PMBCL, immunotherapy, CRS, checkpoint inhibitors, bullous erythema, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Anti-CD19 chimeric antigen receptor (CAR) T cell therapy actually represents the standard of care for multiple relapsed or refractory primary mediastinal B-cell lymphoma (r/r PMBCL). Checkpoint inhibitors, such as pembrolizumab, appear to be a safe and effective treatment strategy for patients who are ineligible for or resistant to autologous stem cell transplantation. Although preclinical studies suggested that checkpoint inhibitors may enhance the vitality and anti-tumor activity of CAR T cells, there are no substantial/robust clinical data about the immune-mediated toxicity of their association. We describe a case of a severe cutaneous adverse event arising immediately after Cytokine Release Syndrome (CRS) on day +6 from CAR T cells infusion in a young r/r PMBCL patient who previously received pembrolizumab. These skin lesions were interpreted as an immune mediated adverse event, considering their prompt improvement and fully recovering achieved with the addition of immunoglobulin infusion to systemic steroid therapy. This case of life-threatening cutaneous adverse event calls for further investigations about off-target immune-related adverse events deriving from the combination of CAR T cell therapy and checkpoint inhibition, whose synergic therapeutic effect is promising.

Published
2023
Full Text
View/download PDF

2. Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study

Author

Michele Malagola, MD, Nicola Polverelli, MD, Massimo Martino, MD, Francesca Patriarca, MD, Benedetto Bruno, MD, Luisa Giaccone, MD, Giovanni Grillo, MD, Stefania Bramanti, MD, Paolo Bernasconi, MD, Marco De Gobbi, MD, Annalisa Natale, MD, Elisabetta Terruzzi, MD, Attilio Olivieri, MD, Patrizia Chiusolo, MD, Angelo Michele Carella, MD, Marco Casini, MD, Enrico Maffini, MD, Chiara Nozzoli, MD, Patrizio Mazza, MD, Simona Bassi, Francesco Onida, MD, Adriana Vacca, MD, Sadia Falcioni, MD, Mario Luppi, MD, Anna Paola Iori, MD, Vincenzo Pavone, MD, Cristina Skert, MD, Paola Carluccio, MD, Carlo Borghero, MD, Anna Proia, MD, Carmine Selleri, MD, Vicky Rubini, MD, Nicoletta Sacchi, MD, Elena Oldani, MD, Francesca Bonifazi, MD, Fabio Ciceri, MD, Domenico Russo, MD, Simona Bernardi, Mirko Farina, Maria Fiore, Maria Teresa Lupo Stanghellini, Renato Fanin, Danilo Giuseppe Faraci, Luca Castagna, Anna Amelia Colombo, Paolo Nicoli, Stella Santarone, Ilaria Scortechini, Elisabetta Metafuni, Emanuela Merla, Irene Cavattoni, Ilaria Cutini, Annamaria Mazzone, Giorgia Saporiti, Filippo Antonio Canale, Eugenia Piras, Piero Galieni, Giulia Debbia, Ursula La Rocca, Anna Mele, Francesca Carobolante, Francesca Elice, and Fulvia Fanelli

Subjects
Surgery, RD1-811
Abstract

Background. The conditioning regimens with different alkylators at different doses can influence the outcome of allogeneic stem cell transplantation (SCT), but conclusive data are missing. Methods. With the aim to analyze real-life allogeneic SCTs performed in Italy between 2006 and 2017 in elderly patients (aged >60 y) with acute myeloid leukemia or myelodysplastic syndrome, we collected 780 first transplants data. For analysis purposes, patients were grouped according to the type of alkylator included in the conditioning (busulfan [BU]-based; n = 618; 79%; treosulfan [TREO]-based; n=162; 21%). Results. No significant differences were observed in nonrelapse mortality, cumulative incidence of relapse, and overall survival, although in the TREO-based group, we observed a greater proportion of elderly patients (P

Published
2023
Full Text
View/download PDF

3. Multi‑parametric MRI in the diagnosis and scoring of gastrointestinal acute graft‑versus‑host disease

Author

Francesca Maccioni, Ursula La Rocca, Alberto Milanese, Ludovica Busato, Arianna Cleri, Mariangela Lopez, Lucia Manganaro, Carlo De Felice, Cira Di Gioia, Anna Rita Vestri, Carlo Catalano, and Anna Paola Iori

Subjects
infammation, magnetic resonance imaging (MRI), hematopoietic stem cell transplantation, graft vs host disease, gastrointestinal tract, Radiology, Nuclear Medicine and imaging, General Medicine
Abstract

Objectives Acute gastrointestinal graft-versus-host disease (GI-aGVHD) is a severe complication of allogeneic hematopoietic stem cell transplantation (HSCT). Diagnosis relies on clinical, endoscopic, and pathological investigations. Our purpose is to assess the value of magnetic resonance imaging (MRI) in the diagnosis, staging, and prediction of GI-aGVHD-related mortality. Methods Twenty-one hematological patients who underwent MRI for clinical suspicion of acute GI-GVHD were retrospectively selected. Three independent radiologists, blinded to the clinical findings, reanalyzed MRI images. The GI tract was evaluated from stomach to rectum by analyzing fifteen MRI signs suggestive of intestinal and peritoneal inflammation. All selected patients underwent colonoscopy with biopsies. Disease severity was determined on the basis of clinical criteria, identifying 4 stages of increasing severity. Disease-related mortality was also assessed. Results The diagnosis of GI-aGVHD was histologically confirmed with biopsy in 13 patients (61.9%). Using 6 major signs (diagnostic score), MRI showed 84.6% sensitivity and 100% specificity in identifying GI-aGVHD (AUC = 0.962; 95% confidence interval 0.891–1). The proximal, middle, and distal ileum were the segments most frequently affected by the disease (84.6%). Using all 15 signs of inflammation (severity score), MRI showed 100% sensitivity and 90% specificity for 1-month related mortality. No correlation with the clinical score was found. Conclusion MRI has proved to be an effective tool for diagnosing and scoring GI-aGVHD, with a high prognostic value. If larger studies will confirm these results, MRI could partly replace endoscopy, thus becoming the primary diagnostic tool for GI-aGVHD, being more complete, less invasive, and more easily repeatable. Key Points • We have developed a new promising MRI diagnostic score for GI-aGVHD with a sensitivity of 84.6% and specificity of 100%; results are to be confirmed by larger multicentric studies. • This MRI diagnostic score is based on the six MRI signs most frequently associated with GI-aGVHD: small-bowel inflammatory involvement, bowel wall stratification on T2-w images, wall stratification on post-contrast T1-w images, ascites, and edema of retroperitoneal fat and declivous soft tissues. • A broader MRI severity score based on 15 MRI signs showed no correlation with clinical staging but high prognostic value (100% sensitivity, 90% specificity for 1-month related mortality); these results also need to be confirmed by larger studies.

Published
2023

5. Management of oral leukoplakia in patients with Fanconi anemia

Author

Roberto Pippi, Cira Di Gioia, Ursula La Rocca, Amelia Bellisario, and AnnaPaola Iori

Subjects
oral squamous cell carcinoma, Otorhinolaryngology, epithelial dysplasia, risk factors, allogeneic hematopoietic stem cell transplantation, excisional biopsy, General Dentistry, Pathology and Forensic Medicine
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results